Comparison · NCT02374021-sae
Triple Therapy (MTX+SSZ+HCQ) vs TNF Inhibitor (Etanercept or Adalimumab): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Triple Therapy (MTX+SSZ+HCQ) vs TNF Inhibitor (Etanercept or Adalimumab): serious adverse events. Trial comparisons, record NCT02374021-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02374021-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.05 | 0.0196 | 0.122 | wilson | |
| Risk in group 2 | 0.127 | 0.0702 | 0.218 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0766 | -0.173 | 0.0146 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.395 | 0.129 | 1.21 | log | |
| Odds ratio, group 1 over group 2 | 0.363 | 0.109 | 1.21 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Triple Therapy (MTX+SSZ+HCQ) than on TNF Inhibitor (Etanercept or Adalimumab) | 13.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Triple Therapy (MTX+SSZ+HCQ) | Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate \[MTX\]).~Methotrexate: Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.~Sulfasalazine: 1 gm bid~Hydroxychloroquine: 200 mg twice daily, not to exceed 6.5mg/kg | 4 | 80 | EG000 |
| Group 2 | TNF Inhibitor (Etanercept or Adalimumab) | etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate, plus hydroxychloroquine, for subjects who were taking this at screening). Biologic treatment will be assigned randomly.~Methotrexate: Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.~Etanercept: 50 mg SC weekly~Adalimumab: 40 mg SQ every other week | 10 | 79 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 24 weeks
Source ClinicalTrials.gov
Trial
- Title
- Treatments Against RA and Effect on FDG-PET/CT
- NCT number
- NCT02374021
- Phases
- PHASE4
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
- Lead sponsor
- Brigham and Women's Hospital
- Results first posted
- 2022-10-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02374021?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02374021-sae